Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 922 | 167 | 714 |
| Samples | 333 | 73 | 251 |
| Peptides | 269 | 46 | 218 |
Function
NXF1 · Nuclear RNA export factor 1
This gene is one member of a family of nuclear RNA export factor genes. Common domain features of this family are a noncanonical RNP-type RNA-binding domain (RBD), 4 leucine-rich repeats (LRRs), a nuclear transport factor 2 (NTF2)-like domain that allows heterodimerization with NTF2-related export protein-1 (NXT1), and a ubiquitin-associated domain that mediates interactions with nucleoporins. The LRRs and NTF2-like domains are required for export activity. Alternative splicing seems to be a common mechanism in this gene family. The encoded protein of this gene shuttles between the nucleus and the cytoplasm and binds in vivo to poly(A)+ RNA. It is the vertebrate homologue of the yeast protein Mex67p. The encoded protein overcomes the mRNA export block caused by the presence of saturating amounts of CTE (constitutive transport element) RNA of type D retroviruses. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 249 amino-acid changes on canonical ENST00000294172 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NXF1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NXF1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| Rhabdomyosarcoma | 6/33 18% | 1/171 1% |
| Endometrial Carcinoma | 3/42 7% | 15/612 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 9/422 2% |
| Colorectal Carcinoma | 15/143 10% | 40/3239 1% |
| Melanoma | 0/210 0% | 27/1899 1% |
| Bladder Carcinoma | 2/58 3% | 11/956 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 12/1390 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Neuroendocrine Tumour | 2/154 1% | 5/577 1% |
| Gastric Carcinoma | 2/74 3% | 16/1809 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Other Solid Cancers | 2/94 2% | 12/1515 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 5/810 1% |
| Hepatocellular Carcinoma | 1/46 2% | 16/2210 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 16/2550 1% |
| Head and Neck Carcinoma | 0/85 0% | 8/1574 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 12/2534 0% |
| Ovarian Carcinoma | 4/109 4% | 1/998 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Breast Carcinoma | 2/144 1% | 12/3264 0% |
| Glioma | 0/52 0% | 9/2127 0% |
| Biliary Tract Carcinoma | 1/54 2% | 3/950 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
Mutation Distribution
Where NXF1 is mutated · all tissues, split by cell line vs tissue
How many mutations in NXF1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 922 mutations in NXF1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|